Analysis of multiple steroids in saliva in the EPAD study
AMYPAD is a European project to establish the true value of amyloid PET in a diagnostic and prognostic setting (http://www.amypad.eu/). This 5-year project is a collaboration between industry (GEHC, Piramal, Janssen, Ixico) and academic partners funded by the IMI-2 program (total budget 27 million euro). Throughout Europe we will recruit 900 memory clinic patients and 3100 preclinical or prodromal AD subjects from natural history cohorts. Up to 50% of subjects will undergo dynamic scanning and have repeat imaging, for a total of 6000 amyloid PET scans. Main study goals include 1) diagnostic impact including patient-reported outcomes and healthcare resource utilization, 2) prognostic value and enrichment of treatment trials, and 3) quantitative assessment of treatment effects.
In close collaboration with EPAD (www.ep-ad.org), the cohorts will be followed with careful longitudinal monitoring and MRI to determine (surrogate) outcomes of cognitive decline and neurodegeneration. Led by VUmc, the consortium brings together a word-class team of highly synergistic partners to form a pan- European network including the most active PET sites. This will ensure effective access to patients and also maximise exposure to technical knowledge and disease modelling. In addition, AMYPAD will develop expertise in image data collection, including β-amyloid PET and MRI data from the EPAD project.
Interested to read more on how you can join? We are currently looking for a (senior) postdoc that will help develop and implement the AMYPAD project in close collaboration with the project leader spanning from research to implementation.
Related posts
